Search results
Showing 241 to 255 of 1044 results for criteria
routing decisions for highly specialised technologies, using existing criteria. These criteria will be reviewed in the...
Upadacitinib for treating active non-radiographic axial spondyloarthritis (TA861)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating active non-radiographic axial spondyloarthritis in adults.
Medical technologies evaluation programme process guide (PMG34)
Medical technologies evaluation programme process guide
Show all sections
- 1 Introduction
- 2 The medical technologies evaluation programme
- 3 Who is involved in the medical technologies evaluation programme
- 4 Identifying, selecting and routing technologies for evaluation
- 5 How medical technologies guidance is developed
- 6 Resolution
- 7 Publishing medical technologies guidance
- 8 Reviews
Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making
NICE has developed a Medtech Innovation Briefing (MIB) on the SpyGlass direct visualisation system for diagnostic and therapeutic procedures during endoscopy of
Evidence-based recommendations on ruxolitinib (Jakavi). This drug is for adults with disease-related splenomegaly or symptoms caused by primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only if they have intermediate-2 or high-risk disease.
resources are for users in England only. Find out more about our eligibility criteria . If you work somewhere else in the UK, you can...
Evidence-based recommendations on certolizumab pegol (Cimzia) and secukinumab (Cosentyx) for treating active psoriatic arthritis in adults.
Cabozantinib for untreated advanced renal cell carcinoma (TA542)
Evidence-based recommendations on cabozantinib (Cabometyx) for untreated advanced renal cell carcinoma in adults.
Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic (secondary) breast cancer in adults who have had only 1 course of chemotherapy.
View recommendations for TA515Show all sections
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy (TA713)
Evidence-based recommendations on nivolumab (Opdivo) for advanced non-squamous non-small-cell lung cancer in adults after chemotherapy.
Cemiplimab for treating advanced cutaneous squamous cell carcinoma (TA802)
Evidence-based recommendations on cemiplimab (Libtayo) for metastatic or locally advanced cutaneous squamous cell carcinoma in adults.
NICE's impact on innovative medicines for childhood conditions
Attention deficit hyperactivity disorder: diagnosis and management (NG87)
This guideline covers recognising, diagnosing and managing attention deficit hyperactivity disorder (ADHD) in children, young people and adults. It aims to improve recognition and diagnosis, as well as the quality of care and support for people with ADHD.
Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis.